MMSI

• Neil W. Peterson resigned for good reason effective March 5, 2027, after more than 32 years with the company.
• Sheri Lewis was appointed Executive Vice President of Global Operations effective August 31, 2026.
• Lewis's employment agreement provides a $600,000 base salary, a $400,000 signing bonus, and a target bonus of 60% of base salary.
• Lewis previously served as Chief Supply Chain and Operations Officer at Skin Health Systems and held senior roles at Avantor, Medtronic, and Honeywell.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• GAAP operating margin was 14.4% versus 12.3% in Q2 2025; non-GAAP operating margin was 22.6% versus 21.2%.
• GAAP net income was $38.8 million versus $32.6 million in Q2 2025; non-GAAP net income was $71.3 million versus $61.0 million.
• Updated full-year 2026 revenue guidance to $1.631-$1.643 billion (8% Y/Y growth) and non-GAAP EPS to $4.25-$4.35 (11%-14% growth).
• Cash and cash equivalents were $448.7 million with total debt of $747.5 million as of June 30, 2026.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Shareholders approved the 2026 Equity Incentive Plan (2.7 million shares authorized) and the 2026 Employee Stock Purchase Plan.
• The advisory say-on-pay proposal passed with 48,835,995 votes for and 1,415,355 against.
• Shareholders ratified Deloitte & Touche LLP as independent auditor for fiscal year 2026.
• The board adopted Fifth Amended and Restated Bylaws on May 14, 2026, updating remote meeting, universal proxy, and indemnification provisions.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• GAAP operating margin was 11.6% vs. 11.5% in prior year; non-GAAP operating margin was 19.7% vs. 19.3%.
• Free cash flow was $24.7 million, up 26% year-over-year.
• Updated full-year 2026 guidance: revenue of $1.612-$1.634 billion (6%-8% growth) and non-GAAP EPS of $4.01-$4.15 (5%-8% growth).
• Acquired View Point Medical on April 1, 2026 for $140 million; divested DualCap product line for $28 million in February 2026.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Merit Medical Systems, Inc. furnished historical revenue disaggregated by Foundational and Therapeutic categories for years ended Dec 31, 2022-2025.
• Foundational revenue grew from $862.4M in 2022 to $1,028.5M in 2025; Therapeutic revenue grew from $288.6M to $487.4M.
• Quarterly revenue for 2025 ranged from $355.4M (Q1) to $393.9M (Q4), compared to $323.5M to $355.2M in 2024.
• The information is furnished under Regulation FD and does not restate previously reported financial statements.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Merit Medical Systems, Inc. acquired View Point Medical, Inc. in a merger, making View Point a wholly-owned subsidiary.
• Total consideration is approximately $140 million, with $90 million paid in cash at closing and two deferred payments of $25 million each due on the first and second anniversaries of closing.
• The acquisition is expected to contribute $2-4 million in revenue for 2026 and $14-16 million for 2027, with dilution to 2026 non-GAAP EPS of about $0.05.
• The press release was furnished under Item 7.01 Regulation FD Disclosure, with the exhibit included as Exhibit 99.1.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Full-year 2025 revenue was $1.516 billion, up 12%; GAAP EPS was $2.13, up 5%.
• Q4 2025 GAAP operating margin was 13.8% (vs. 10.3% prior year); non-GAAP operating margin was 21.0% (vs. 19.6%).
• FY2025 GAAP operating margin was 12.2% (vs. 11.5% prior year); non-GAAP operating margin was 20.3% (vs. 19.0%).
• FY2026 guidance: revenue of $1.610-$1.630 billion (up 6%-8%) and non-GAAP EPS of $4.01-$4.15 (up 5%-8%).

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Lampropoulos' resignation followed the end of his Executive Chair employment on January 3, 2026, and his earlier resignation as President and CEO.
• F. Ann Millner, Ed.D., formerly Lead Independent Director, was appointed Chair of the Board effective January 5, 2026.
• The Board reduced its size from eleven to ten members effective January 5, 2026.
• Merit entered a consulting agreement with Lampropoulos for three months at $250,000 per month.

2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits